Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May 29;188(11):2974-2991.e20.
doi: 10.1016/j.cell.2025.03.031. Epub 2025 Apr 15.

DNA binding and mitotic phosphorylation protect polyglutamine proteins from assembly formation

Affiliations

DNA binding and mitotic phosphorylation protect polyglutamine proteins from assembly formation

Shady Saad et al. Cell. .

Abstract

Polyglutamine (polyQ) expansion is associated with pathogenic protein aggregation in neurodegenerative disorders. However, long polyQ tracts are also found in many transcription factors (TFs), such as FOXP2, a TF implicated in human speech. Here, we explore how FOXP2 and other glutamine-rich TFs avoid unscheduled assembly. Throughout interphase, DNA binding, irrespective of sequence specificity, has a solubilizing effect. During mitosis, multiple phosphorylation events promote FOXP2's eviction from chromatin and supplant the solubilizing function of DNA. Further, human-specific amino acid substitutions linked to the evolution of speech map to a mitotic phospho-patch, the "EVO patch," and reduce the propensity of the human FOXP2 to assemble. Fusing the pathogenic form of Huntingtin to either a DNA-binding domain, a phosphomimetic variant of this EVO patch, or a negatively charged peptide is sufficient to diminish assembly formation, suggesting that hijacking mechanisms governing solubility of glutamine-rich TFs may offer new strategies for treatment of polyQ expansion diseases.

Keywords: FOXP2; Huntington's disease; amyloid; evolution; glutamine-rich proteins; human speech; language; polyglutamine; protein assemblies; transcription factors.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests S.S., T.S., D.F.J., and J.W. filed a provisional patent application related to this work. J.W. is a paid scientific advisory board member at Camp4 Therapeutics. J.W. is an advisory board member at Cell Press journals, including Cell, Molecular Cell, and Developmental Cell.

References

    1. Lambert SA, Jolma A, Campitelli LF, Das PK, Yin Y, Albu M, Chen X, Taipale J, Hughes TR, and Weirauch MT (2018). The Human Transcription Factors. Cell 172, 650–665. 10.1016/j.cell.2018.01.029. - DOI - PubMed
    1. Kim S, and Wysocka J (2023). Deciphering the multi-scale, quantitative cis-regulatory code. Mol Cell 83, 373–392. 10.1016/j.molcel.2022.12.032. - DOI - PMC - PubMed
    1. Spitz F, and Furlong EE (2012). Transcription factors: from enhancer binding to developmental control. Nat Rev Genet 13, 613–626. 10.1038/nrg3207. - DOI - PubMed
    1. Seipel K, Georgiev O, and Schaffner W (1992). Different activation domains stimulate transcription from remote (‘enhancer’) and proximal (‘promoter’) positions. EMBO J 11, 4961–4968. 10.1002/j.1460-2075.1992.tb05603.x. - DOI - PMC - PubMed
    1. Udupa A, Kotha SR, and Staller MV (2024). Commonly asked questions about transcriptional activation domains. Curr Opin Struct Biol 84, 102732. 10.1016/j.sbi.2023.102732. - DOI - PMC - PubMed

LinkOut - more resources